PhaseBio Pharmaceuticals, Inc. — Wednesday, November 21st 2018 at 1:00pm UTC
MALVERN, Pa. and SAN DIEGO, Nov. 21, 2018 (GLOBE NEWSWIRE) — PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for orphan diseases, with an initial focus on cardiopulmonary disorders, today announced it will report financial and business results for the third quarter of 2018 on November 29, 2018, after the close of the U.S. financial markets.
For more information on PhaseBio and to receive PhaseBio press releases, please visit the Investors section of the company’s website at https://investors.phasebio.com and register for email alerts.
PhaseBio Pharmaceuticals, Inc., is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies to treat orphan diseases, with an initial focus on cardiopulmonary disorders. The company’s lead development candidate is PB2452, a novel reversal agent for the antiplatelet therapy ticagrelor. PhaseBio is also leveraging its proprietary elastin-like polypeptide (ELP) technology platform to develop therapies with the potential for less-frequent dosing and improved pharmacokinetics. PhaseBio’s second product candidate PB1046, which is based on ELP, is a once-weekly vasoactive intestinal peptide receptor agonist for the treatment of pulmonary arterial hypertension (PAH).
PhaseBio is located in Malvern, PA and San Diego, CA. For more information, please visit www.phasebio.com.
PhaseBio Pharmaceuticals, Inc.
Chief Financial Officer